APONTIS PHARMA and Develco Pharma enter into a development partnership for the launch of two unique pills with pan-European intellectual property rights


DGAP-News: APONTIS PHARMA AG / Key word(s): Product launch
APONTIS PHARMA and Develco Pharma enter into a development partnership for the launch of two unique pills with pan-European intellectual property rights
05.05.2022 / 07:30
The issuer is solely responsible for the content of this announcement.

APONTIS PHARMA and Develco Pharma enter into a development partnership for the launch of two unique pills with pan-European intellectual property rights

  • Further expansion of the medium-term single pill portfolio for the treatment of hypertension with two new single pills

  • APONTIS PHARMA obtains the rights (IP – Intellectual Property) on the unique pills for European countries

Monheim am Rhein, May 5, 2022. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in unit pills on the German market, is expanding its partner network as well as its product portfolio. Today, the Single Pill Company announced a new development cooperation with Swiss Develco Pharma. The object is the contract development of two unique pills, each containing a combination of two leading active ingredients for the treatment of cardiovascular disease. Market launch is scheduled for 2025. These two developments will further strengthen APONTIS PHARMA’s portfolio in the medium term. This means that in addition to the six single pills in the short-term pipeline, there are now three single-pill products in the mid-term pipeline; seven Single Pills have already been successfully launched on the market.

APONTIS PHARMA will again own the national EU-wide rights (IP – intellectual property) on the combined products, Develco will have other partners outside the EU. Therefore, this opens up further growth potential for the Company in its Europe-wide licensing for marketing and distribution. In Germany alone, more than 700,000 patients are currently taking a loose combination of the two active ingredients – and the incidence is increasing.

The one-tablet therapeutic approach has proven itself. By combining up to three active ingredients in one single tablet, patients are more likely to take the drug than with a free combination. As such, the single pill is the basis for more effective and therefore more effective treatment. Compared to conventional therapies, single pills sustainably reduce event rates and hospital stays. The success of the therapeutic strategy is proven by the START study conducted in 2019. The results show that patients benefit from a single-pill regimen compared to an equivalent multi-pill regimen.

“The partnership with Develco Pharma opens doors to meet the demand of German and European patients for unique pills for the treatment of hypertension in an even more comprehensive and targeted way in the future. At the same time, we are getting closer to our goal of 20 unique pills by 2026. During the current fiscal year, three more unique pills will become effective in terms of sales and profits with their market launch, and three unique pills in the following year 2023. We are very happy to have won additional competent and experienced partners in this new cooperation, who share our vision for a more effective and innovation-driven therapy,” said Karlheinz Gast , CEO of APONTIS PHARMA AG.

“Innovation and expertise in the development of complex drugs are the cornerstones of our entrepreneurial activities. With this in mind, two healthcare companies are now pooling their expertise to improve the quality of life of a growing group of patients. We are very excited about this partnership, as APONTIS PHARMA’s strong marketing and sales skills and our extensive product development expertise are very promising conditions for a successful partnership,” says Dr. Martin Renner, CEO of Develco Pharma Schweiz AG.


APONTIS PHARMA AG is a leading pharmaceutical company specializing in unit pills in Germany. Single pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of unique pills and other pharmaceutical products, with a particular focus on cardiovascular diseases. Since 2013, APONTIS has successfully launched several single-pill products for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its head office in Monheim am Rhein, APONTIS PHARMA is established in one of the main pharmaceutical and chemical regions of Europe. From there, the company maintains an extensive network with research-based pharmaceutical companies and a customer target group of approx. 23,000 doctors in Germany. For more information about APONTIS PHARMA, please visit www.apontis-pharma.de.

About Develco Pharma:

Headquartered in Pratteln/Switzerland, Develco Pharma is a Swiss-German pharmaceutical company specializing in the development and manufacture of oral modified, sustained and time release drugs containing known active ingredients. Founded in 2006, the company now has 130 employees. In Germany, a state-of-the-art production plant for analgesics and other indications has been operational in Schopfheim, in the Baden region, since 2016. Develco identifies and defines pharmaceutical products containing known active ingredients and develops generic products , hybrids, value added and innovative formulations supported by clinical data for delayed or modified release of active ingredients. With its experience and spirit of innovation, the company has established itself as an internationally recognized supplier of pharmaceutical products for the treatment of several disease areas. Develco Pharma’s customer base includes global pharmaceutical groups. The company has some 180 total marketing authorizations (products of different strengths) in Europe, the United States, the Middle East, South Africa, Asia and Australia. For more information, visit: www.develco.ch.


Investor Relations
[email protected]
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. ten
40789 Monheim am Rhein


CROSS ALLIANCE communication GmbH
Sven Pauly
Sara Pinto
[email protected]
T: +49 89 125 09 0330

05.05.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de


Comments are closed.